Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 13, Issue 575, Pages eabb6295
Publisher
American Association for the Advancement of Science (AAAS)
Online
2021-01-07
DOI
10.1126/scitranslmed.abb6295
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Emerging Landscape of Immune Cell Therapies
- (2020) Evan W. Weber et al. CELL
- Tuning the Antigen Density Requirement for CAR T-cell Activity
- (2020) Robbie G. Majzner et al. Cancer Discovery
- Patterns of substrate affinity, competition and degradation kinetics underlie biological activity of thalidomide analogs
- (2019) Adam S. Sperling et al. BLOOD
- A safe and potent anti-CD19 CAR T cell therapy
- (2019) Zhitao Ying et al. NATURE MEDICINE
- The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
- (2019) Katrin Mestermann et al. Science Translational Medicine
- Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide
- (2019) Melissa Works et al. MOLECULAR CANCER THERAPEUTICS
- Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial
- (2019) E. Antonio Chiocca et al. Science Translational Medicine
- Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
- (2019) Noelle V. Frey et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthetic Biology: Immunotherapy by Design
- (2018) Matthew J. Brenner et al. Annual Review of Biomedical Engineering
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
- (2018) Jang Hwan Cho et al. CELL
- The dTAG system for immediate and target-specific protein degradation
- (2018) Behnam Nabet et al. Nature Chemical Biology
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Pharmacology of T Cell Therapies
- (2018) Michael C. Milone et al. Molecular Therapy-Methods & Clinical Development
- SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
- (2018) Mary E. Matyskiela et al. Nature Chemical Biology
- Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome
- (2018) Katherine A Donovan et al. eLife
- Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
- (2018) Judith Feucht et al. NATURE MEDICINE
- Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
- (2018) Quinlan L. Sievers et al. SCIENCE
- Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells
- (2017) Iulia Diaconu et al. MOLECULAR THERAPY
- The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy
- (2017) Felipe Bedoya et al. MOLECULAR THERAPY
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
- (2017) Jian An et al. Nature Communications
- Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy
- (2016) Oladapo O. Yeku et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
- (2016) Nianhang Chen et al. CLINICAL PHARMACOKINETICS
- Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
- (2016) Georg Petzold et al. NATURE
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- The novel mechanism of lenalidomide activity
- (2015) E. C. Fink et al. BLOOD
- Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses
- (2015) S Kuramitsu et al. CANCER GENE THERAPY
- Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
- (2015) Jan Krönke et al. NATURE
- Tunable and reversible drug control of protein production via a self-excising degron
- (2015) Hokyung K Chung et al. Nature Chemical Biology
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
- (2015) C.-Y. Wu et al. SCIENCE
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
- (2014) Eric S. Fischer et al. NATURE
- Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs
- (2014) Philip P Chamberlain et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
- (2014) M. Hudecek et al. Cancer Immunology Research
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Cell-Based Therapeutics: The Next Pillar of Medicine
- (2013) M. A. Fischbach et al. Science Translational Medicine
- Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor
- (2012) Megan E. Prosser et al. MOLECULAR IMMUNOLOGY
- Small-molecule displacement of a cryptic degron causes conditional protein degradation
- (2011) Kimberly M Bonger et al. Nature Chemical Biology
- Chemical Inducers of Targeted Protein Degradation
- (2010) Kanak Raina et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An auxin-based degron system for the rapid depletion of proteins in nonplant cells
- (2009) Kohei Nishimura et al. NATURE METHODS
- Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib
- (2008) R. Weichsel et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now